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Discussion
Dr Joseph B. Zwischenberger (Galveston, Tex). As one ap-
proaches the problem of an off-the-shelf artificial lung, the spec-
trum ranges from aplastic artificial lung all the way to transspecies
transplant. You are to be congratulated for persisting in your work
of trying to accomplish transspecies transplantation, which has the
promise for an off-the-shelf artificial lung.
This work has been ongoing for 10 or 15 years, and it strikes
me that creating a transgenic knockout swine model is very diffi-
cult. You did not mention what it takes to create that. Could you
please recap that for us?
Second, I am having some difficulty in trying to put together
the accomplishment of a 2-hour survival in two of three pigs. How
is two of three an advance?
Finally, you mentioned intravascular coagulation as being the
hallmark of the failure of these transplanted lungs, and you men-
tioned platelet activation and intravascular thrombosis. Could you
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tease out which is the chicken and which is the egg? Are you
activating platelets, which are then causing intravascular coagula-
tion? Are you causing intravascular coagulation, which is then
activating platelets? It may help to define your future strategies.
Dr Nguyen. Thank you, Dr Zwischenberger. To answer your
first question about how to make the GalT-KO lungs, I wish I knew
because then I would be able to make them myself and make them
more available. These are very precious animals because they are
genetically engineered by only a few groups and we have to share
them among many investigators in the field. My understanding is
that they can either be cloned or bred naturally. The problem is that
they do not breed as well as the other domestic swine and some-
times they have a higher rate of perinatal mortality as well.
However, if they survive to adulthood, then they have no other
health problems so far as we know.
To answer your second question about whether two of three
GalT-KO lungs surviving at 4 hours is an achievement, I think this
is phenomenal. If you attach wild-type lungs or even transgenic
MCP lungs untreated to a baboon, you do not have any life-
supporting function beyond minutes. In the past many other in-
vestigators did in vivo transplant. You have to do many treatments
to the recipient in terms of antibody absorption before surgery. A
lot of manipulation to the recipient sometimes is not beneficial to
the recipient. Thus I think two of three lungs beyond 1 hour and 4
hours is significant.
Your third question concerned intravascular thrombosis and
whether the coagulation activation starts first or platelet activation
starts first. I think it is more of a circle feedback loop. If you perfuse
human blood to a pig organ, even in the nonactivated pig endothelial
cells, you do see human prothrombin converted to thrombin, because
pig thrombomodulin is so ineffective at preventing this process.
Human thrombomodulin is very effective in doing this, but not pig
thrombomodulin. Thus you have thrombin formation. Even in the
absence of complement activation, you have thrombin formation first,
and then you could trigger coagulation activation directly from throm-
bin. However, then thrombin can also activate platelets, and activated
platelets can trigger coagulation activation as well. Again, I think it is
more like a circle feedback loop. We have to address both platelet
activation and coagulation activation together to prevent intravascular
thrombosis.
Dr Young Tae Kim (Seoul, South Korea). Did you look at the
von Willebrand factor? We have been doing similar experiments,
and what we found is that when we deplete the von Willebrand
factor by giving vasopressin, the success rate increases. Did you
check it?
Dr Nguyen. Do you mean check for the absence of GalT
antigen in GalT-KO pigs?
Dr Kim. The von Willebrand factor.
Dr Nguyen. Yes. We did not do this ourselves, but the supplier
of the GalT-KO pigs actually confirmed that. Every time they sent
us the pigs, they confirmed that this is indeed GalT-KO.
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